Does Use of the CureResponse (cResponse) Assay Prolong Survival?

An analysis of current trial evidence (as of June 2024)

1. Summary of Current Evidence

Key points:

・ The CureResponse (cResponse) assay is a functional platform for predicting cancer treatment sensitivity.

・ Clinical trials (notably a multicenter Phase II trial) have demonstrated high predictive accuracy for treatment response (sensitivity ~90%, specificity ~91.6%).

・ However, no published trial to date has demonstrated (in peer-reviewed or public registries) that use of cResponse-guided therapy selection results in a significant improvement in overall survival (OS) or progression-free survival (PFS) for patients compared to standard care.

2. Detail From Key Trials and Publications

Phase II cResponse Trial Highlights

・ Objective: Assess the assay’s ability to predict patient response, not a survival endpoint.

・ Design/Endpoints: Focused on response rate, sensitivity, and specificity.**

・ Survival Endpoints: Not primary or reported in available publications and interim results.

・ Source:

・ ESMO MAP 2023 Clinical Trial Poster, PDF

・ Imperial College London cResponse study portal

Excerpt from ESMO MAP 2023 PDF:

"We report high sensitivity and specificity for ex vivo prediction of in vivo drug response... Survival analyses await further follow-up."

(see PDF, Section: Results & Conclusions)

3. Gaps and Ongoing Research

・ Ongoing Studies: Longer-term OS and PFS analysis is pending in ongoing or planned trials. Interim publications universally state that survival data are "awaited" or "follow-up ongoing", and/or that it is not powered to detect OS differences.

・ No current trial reporting OS/PFS benefit as a published outcome.

If looking for a biomarker-guided improvement in survival:

As of now, the cResponse assay is validated for predicting response, not for showing prolonged survival following its clinical use.

4. Comparison With Broader Literature

・ Similar functional assays are frequently validated using response rate and negative predictive value, with survival impact lagging.**

・ PubMed: "Relationship between Overall Survival and Response..." (non-cResponse, but related concept)

5. Graphical Illustration

While there are general illustrations of survival analysis in clinical research:

Currently, no published Kaplan-Meier OS plots are available for cResponse-based patient stratification.

6. Conclusion Table

| Assay / Study | Demonstrated OS/PFS Prolongation | Status | Main Endpoint |

|------------------|----------------------------------|----------------|----------------------|

| cResponse (Phase II) | ❌ Not yet published | Recruiting/Interim | Treatment sensitivity |

| cResponse (Any) | ❌ Not yet published | N/A | N/A |

7. Takeaway for Translational/Clinical AI & Oncology Practice

・ Clinical utility: Strong evidence for predicting response, not (yet) outcome-improving.

・ Next steps: Await publication of OS or PFS data as trial follow-up matures or future RCTs are powered for survival.

・ Implications: Promising for AI-guided treatment selection, but not practice-changing for survival endpoints—yet.

If you want alerts when survival data does become available, consider tracking trial registries or setting up alerts on PubMed and clinicaltrials.gov for “CureResponse” AND “overall survival” updates.

References

・ ESMO MAP 2023 Clinical Trial Poster (PDF)

・ Imperial College cResponse Study

・ PubMed: OS/response relationships in trials

Let me know if you need notifications on future OS/PFS results, or want to discuss trial design strategies to power for survival endpoints in functional assay trials.